| 3.345 -0.625 (-15.74%) | 11-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.55 |
1-year : | 4.98 |
| Resists | First : | 3.89 |
Second : | 4.26 |
| Pivot price | 3.98 |
|||
| Supports | First : | 3.29 |
Second : | 2.74 |
| MAs | MA(5) : | 3.89 |
MA(20) : | 3.96 |
| MA(100) : | 3.86 |
MA(250) : | 4.05 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 26.6 |
D(3) : | 41.3 |
| RSI | RSI(14): 28.5 |
|||
| 52-week | High : | 5.63 | Low : | 2.83 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVO ] has closed below the lower bollinger band by 35.2%. Bollinger Bands are 39.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.43 - 3.45 | 3.45 - 3.47 |
| Low: | 3.24 - 3.27 | 3.27 - 3.29 |
| Close: | 3.3 - 3.35 | 3.35 - 3.38 |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Wed, 05 Nov 2025
Evotec Q3 2025 Earnings Call Transcript - MarketBeat
Wed, 05 Nov 2025
Evotec Shares Drop Over 9% as Weakness in Drug Discovery Drags Nine-Month Results - MSN
Wed, 05 Nov 2025
Evotec SE Finalizes Landmark Agreement with Sandoz for Biologics Site Sale - TipRanks
Wed, 05 Nov 2025
Evotec SE Reports Strategic Progress Amid Revenue Shift - TipRanks
Wed, 05 Nov 2025
Evotec SE (EVO) Reports Q3 results; offers guidance - StreetInsider
Wed, 05 Nov 2025
Evotec SE (EVO) Reports Decline in Q3 Revenues Amid Market Chall - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 355 (M) |
| Shares Float | 131 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 543 (K) |
| Shares Short P.Month | 657 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.76 |
| Profit Margin | -20.1 % |
| Operating Margin | -16.8 % |
| Return on Assets (ttm) | -2.5 % |
| Return on Equity (ttm) | -16.8 % |
| Qtrly Rev. Growth | -6 % |
| Gross Profit (p.s.) | 0.28 |
| Sales Per Share | 2.18 |
| EBITDA (p.s.) | 0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 112 (M) |
| Levered Free Cash Flow | 19 (M) |
| PE Ratio | -6.56 |
| PEG Ratio | 0 |
| Price to Book value | 0.7 |
| Price to Sales | 1.52 |
| Price to Cash Flow | 10.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|